Pregabalin in the Treatment of Herpetic Neuralgia: Results of a Multicenter Chinese Study

Liang, Li‐Jung; Li, Xingang; Zhang, Guozhuan; Sun, Yingjiao; Yu, Hui; Jiao, Jian

doi:10.1111/pme.12564

Cited by 11 publications

(13 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pregabalin is an antiepileptic used for treatment of partial seizures, diabetic neuropathy and post-herpetic neuralgia [18][19][20] . Pregabalin has many advantages over other antiepileptic drugs like lack of any pharmacokinetic interaction with other medications or enzyme induction.…”

Section: Introductionmentioning

confidence: 99%

Preparation and evaluation of floating tablets of pregabalin

Kanwar

Kumar

Sarwal

et al. 2015

Drug Development and Industrial Pharmacy

View full text Add to dashboard Cite

Floating tablets of pregabalin were prepared using different concentrations of the gums (xanthan gum and guar gum), Carbopol 974P NF and HPMC K100. Optimized formulations were studied for physical tests, floating time, swelling behavior, in vitro release studies and stability studies. In vitro drug release was higher for tablet batches containing guar and xanthan gum as compared to the batches containing Carbopol 974P NF. Tablet batches were subjected to stability studies and evaluated by different parameters (drug release, drug content, FTIR and DSC studies). The optimized tablet batch was selected for in vivo pharmacodynamic studies (PTZ induced seizures). The results obtained showed that the onset of jerks and clonus were delayed and extensor phase was abolished with time in treated groups. A significant difference (p > 0.05) was observed in control and treated group behavior indicating an excellent activity of the formulation for a longer period (>12 h).

show abstract

Section: Introductionmentioning

confidence: 99%

Preparation and evaluation of floating tablets of pregabalin

Kanwar

Kumar

Sarwal

et al. 2015

Drug Development and Industrial Pharmacy

View full text Add to dashboard Cite

show abstract

“…The remaining 98 studies were thoroughly examined, and 59 were eliminated for the following reasons: Meta-analysis [ 10 , 13 , 26 - 33 ], were irrelevant to outcomes of the study [ 34 - 55 ], unavailable outcomes [ 56 - 67 ], non-original data [ 68 - 71 ], grouping [ 72 - 77 ], and were nonrandomized studies [ 78 - 82 ]. As a result, 39 studies met the criteria for inclusion in this systematic review and meta-analysis ( Fig.…”

Section: Resultsmentioning

confidence: 99%

Pharmacological and non-pharmacological strategies for preventing postherpetic neuralgia: a systematic review and network meta-analysis

Kim

Choi

et al. 2021

Korean J Pain

View full text Add to dashboard Cite

Background Postherpetic neuralgia (PHN) is a refractory complication of herpes zoster (HZ). To prevent PHN, various strategies have been aggressively adopted. However, the efficacy of these strategies remains controversial. Therefore, we aimed to estimate the relative efficacy of various strategies used in clinical practice for preventing PHN using a network meta-analysis (NMA). Methods We performed a systematic and comprehensive search to identify all randomized controlled trials. The primary outcome was the incidence of PHN at 3 months after acute HZ. We performed both frequentist and Bayesian NMA and used the surface under the cumulative ranking curve (SUCRA) values to rank the interventions evaluated. Results In total, 39 studies were included in the systematic review and NMA. According to the SUCRA value, the incidence of PHN was lower in the order of continuous epidural block with local anesthetics and steroids (EPI-LSE), antiviral agents with subcutaneous injection of local anesthetics and steroids (AV + sLS), antiviral agents with intracutaenous injection of local anesthetics and steroids (AV + iLS) at 3 months after acute HZ. EPI-LSE, AV + sLS and AV + iLS were also effective in preventing PHN at 1 month after acute HZ. And paravertebral block combined with antiviral and antiepileptic agents was effective in preventing PHN at 1, 3, and 6 months. Conclusions The continuous epidural block with local anesthetics and steroid, antiviral agents with intracutaneous or subcutaneous injection of local anesthetics and a steroid, and paravertebral block combined with antiviral and antiepileptic agents are effective in preventing PHN.

show abstract

“…The main reason for PHN has been shown to be ongoing painful signal input during the acute inflammatory phase, which causes central nervous system changes that generate chronic pain (20). Recently, attempts to reduce the incidence of PHN have been bolstered by the findings of clinical trials that anticonvulsants, opioid analgesics, tricyclic antidepressants, or nerve blocks are effective treatments for HZ (21)(22)(23). However, it remains unknown when supplemental pain managements should be started.…”

Section: Wwwpainphysicianjournalcom Discussionmentioning

confidence: 99%

Delayed Initiation of Supplemental Pain Management is Associated with Postherpetic Neuralgia: A Retrospective Study

Yan

2020

Pain Phys

View full text Add to dashboard Cite

Background: Acute pain is a risk factor for developing postherpetic neuralgia (PHN), the most common complication of herpes zoster (HZ). Supplemental analgesics are frequently used in the treatment of acute herpetic pain. However, there are insufficient data regarding when to begin supplemental analgesics, and it is unknown whether the delayed use of supplemental analgesics increases the risk of PHN in high-risk patients. Objectives: This study aimed to evaluate the association between initial time of supplemental pain management and the risk of PHN in high-risk patients. Study Design: Retrospective study. Setting: The Department of Anesthesiology and Pain Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine. Methods: We performed a retrospective study between May 13, 2017 and August 8, 2018 in our clinic. Multivariable logistic regression analysis was conducted to examine the independent factors associated with PHN. Supplemental pain management was defined as any use of opioids, tricyclic antidepressants, or nerve blocks. A subgroup analysis was conducted in patients who received supplemental pain management within the first 30 days of onset. According to the initial time of supplemental pain management, patients were divided into 2 groups: the early treatment group (≤ 14 days), and the late treatment group (> 14 days). The clinical outcomes in these 2 groups was compared for propensity score (PS) matching. Results: A total of 134 patients with HZ aged 50 years or older with moderate to severe pain were enrolled in this study. The delayed initiation of supplemental pain management (> 14 days) (odds ratio, 4.11; 95% confidence interval, 1.69-9.92; P = 0.002) and severity of rash (odds ratio, 2.93; 95% confidence interval, 1.22-7.01; P = 0.016) were independent factors associated with PHN. In the subgroup analysis, after PS matching, there were no significant differences in the baseline clinical parameters between the early and late treatment groups. The incidence of PHN was significantly lower in the early treatment group than the late treatment group (36. 4% vs. 72.7%; P = 0.015). Reduction in pain was also greater in the early treatment group. Limitations: The findings identified in the present study are specific to the patients who were relatively older and with moderate to severe pain. It is impossible to determine from our study whether younger individuals and individuals with mild acute pain will benefit from early supplemental treatments. Furthermore, because of the retrospective nature of the study, there may be some confounders that could not be controlled. Further prospective studies with larger sample sizes and longer follow-up periods are needed. Conclusions: The early use of supplemental pain management may decrease the risk of PHN. It might therefore be beneficial to consider administering supplemental pain management earlier in older patients with moderate to severe acute herpetic pain. Key words: Herpes zoster, postherpetic neuralgia, analgesia, opioid, nerve block, tricyclic antidepressant

show abstract

Pregabalin in the Treatment of Herpetic Neuralgia: Results of a Multicenter Chinese Study

Abstract: Both combination therapy with oxycodone plus pregabalin and oxycodone monotherapy were effective and safe for herpetic neuralgia. In addition, subjects on combination therapy showed shortened time to pain relief, reduced pain intensity, and greater improvement than oxycodone alone.

Cited by 11 publications

References 21 publications

Preparation and evaluation of floating tablets of pregabalin

Preparation and evaluation of floating tablets of pregabalin

Pharmacological and non-pharmacological strategies for preventing postherpetic neuralgia: a systematic review and network meta-analysis

Delayed Initiation of Supplemental Pain Management is Associated with Postherpetic Neuralgia: A Retrospective Study

Contact Info

Product

Resources

About